These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28794366)

  • 21. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
    Ajimizu H; Kim YH; Mishima M
    Med Oncol; 2015 Feb; 32(2):477. PubMed ID: 25556163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
    Carlson JJ; Canestaro W; Ravelo A; Wong W
    J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G; Seto T; Takenoyama M; Ichinose Y
    Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH; Milliken JC; Azada MC; Miller VA; Ali SM; Klempner SJ
    Lung Cancer; 2016 Jan; 91():70-2. PubMed ID: 26464158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
    Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
    Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.
    Bendaly E; Dalal AA; Culver K; Galebach P; Bocharova I; Foster R; Sasane M; Macalalad AR; Guérin A
    Adv Ther; 2017 Jul; 34(7):1673-1685. PubMed ID: 28578501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of complex renal cysts: A complication associated with Crizotinib therapy.
    Chen F; Patel NJ; Legout JD; Caserta MP
    Clin Imaging; 2020 Sep; 65():15-17. PubMed ID: 32353713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
    Caccese M; Ferrara R; Pilotto S; Carbognin L; Grizzi G; Caliò A; Brunelli M; Cuppone F; Petraglia S; Scarpa A; Tortora G; Bria E
    Expert Opin Pharmacother; 2016 Dec; 17(17):2253-2266. PubMed ID: 27682212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
    Larkins E; Blumenthal GM; Chen H; He K; Agarwal R; Gieser G; Stephens O; Zahalka E; Ringgold K; Helms W; Shord S; Yu J; Zhao H; Davis G; McKee AE; Keegan P; Pazdur R
    Clin Cancer Res; 2016 Nov; 22(21):5171-5176. PubMed ID: 27413075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
    Hida T; Nakagawa K; Seto T; Satouchi M; Nishio M; Hotta K; Takahashi T; Ohe Y; Takeda K; Tatsuno M; Asakawa T; Shimada T; Tanaka T; Tamura T
    Cancer Sci; 2016 Nov; 107(11):1642-1646. PubMed ID: 27566263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM
    Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M; Altavilla G; Rosell R
    Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
    Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC
    J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
    Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
    J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
    Toyokawa G; Hirai F; Inamasu E; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
    J Thorac Oncol; 2014 Dec; 9(12):e86-7. PubMed ID: 25393798
    [No Abstract]   [Full Text] [Related]  

  • 37. Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Metro G; Tazza M; Matocci R; Chiari R; Crinò L
    Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
    Cameron L; Solomon B
    Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
    Gadgeel SM; Shaw AT; Govindan R; Gandhi L; Socinski MA; Camidge DR; De Petris L; Kim DW; Chiappori A; Moro-Sibilot DL; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; Yang JC; Han JY; Bordogna W; Golding S; Zeaiter A; Ou SI
    J Clin Oncol; 2016 Dec; 34(34):4079-4085. PubMed ID: 27863201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.